News - Marketing authorisation medicines for human use

40 news items Marketing authorisation medicines for human use

Enter search criteria

Fill in keyword(s) to narrow your search.

Periode

Fill in a starting date and a closing date for the period your query is about: DD-MM-YYYY

Subscribe to news from this organisation

Changes to product information must be made more quickly

Within Europe agreements are regularly made regarding changes to information on medicinal products. In many cases it takes too ...

News item | 14-10-2019 | 14:00

Year-end withdrawals medicines for human use

Withdrawal requests for (parallel) marketing authorisations per 31 December, the so-called 'year-end withdrawals' for medicines ...

News item | 17-09-2019 | 09:00

MEB and ZIN start pilot to accelerate access to innovative medicines

Accelerating patient access to reimbursable innovative medicines has been on the wish list of the government, patient ...

News item | 09-05-2019 | 08:00

Amended policy relating to patented indications

The Medicines Evaluation Board (MEB) will no longer publish the full product information about the active substance of generic ...

News item | 08-05-2019 | 13:00

Brexit: Notification by the European Commission/EMA/CMDh and CMDv about Brexit and EU rules for batch control of medicinal products

On 25 February 2019 the European Commission (EC) published a notice on the European rules for batch control testing of medicinal ...

News item | 05-03-2019 | 14:00

MEB fee rate change as of January 2019

The Medicines Evaluation Board (MEB) is increasing the fee rates for authorisation applications, authorisation changes and the ...

News item | 11-12-2018 | 09:00

Year-end withdrawals

Requests for withdrawal on December 31st (the year-end withdrawals) should be received by the Medicines Evaluation Board (MEB) on ...

News item | 16-10-2018 | 16:00

Information about the Falsified Medicines Directive (FMD)

Update for marketing authorisation holders The Falsified Medicines Directive (FMD) (Directive 2011/62/EU) are measures to prevent ...

News item | 13-07-2018 | 08:00

Amended policy for DHPCs and national implementation of additional risk minimisation measures

The Medicines Evaluation Board (MEB) has amended its policy for Direct Healthcare Professional Communications (DHPCs) and the ...

News item | 11-06-2018 | 15:00

Signal management pilot for limited group of companies

On 22 February 2018 a pilot will start for companies with medicinal products under additional monitoring. As from that date ...

News item | 18-12-2017 | 14:00